Tom Sellig

Tom Sellig, Adare Pharma Solutions, shares how the CDMO is positioning for growth amid U.S. reshoring and oral dose innovation trends.

Tom Sellig on CDMO Innovation and US Manufacturing Growth

, Tom Sellig, CEO, Adare Pharma Solutions, spoke with 

 to offer his perspective on the forces shaping pharmaceutical development and manufacturing today, from advanced dosage form technologies to the regulatory environment and the industry's reshoring momentum.

Sellig sees the current wave of foreign investment into US manufacturing as a meaningful opportunity for contract development and manufacturing organizations (CDMOs). He says, “as we see companies looking to try to invest in the United States, the opportunity for us is to support these complex formulations that are driving patient needs throughout the world today.”

On the innovation front, Sellig highlights 3D printing of tablets as a consequential growth drivers, enabling differentiated formulation profiles and a broader range of release mechanisms. He also points to solubility and bioavailability enhancement as a crowded but evolving space, suggesting Adare is developing proprietary approaches that could outpace currently available technologies.

Sellig also touches on regulatory dynamics, noting that ongoing changes at the FDA are reshaping how CDMOs and pharma companies collaborate. With priority review vouchers, for example, the agency is placing real pressure on development timelines and demanding faster paths to market.

Workforce development is also an important theme of the discussion as Sellig touches on the launch of the "Adare Academy," an internal training initiative covering both scientific hard skills and professional soft skills, designed to reduce turnover and strengthen client service continuity.

On the broader reshoring narrative, Sellig acknowledges the scale of commitments being made, close to $500 billion pledged by large pharma, while remaining pragmatic. "We're focusing on what we can do today, building out selective capacity and capabilities in order to support the industry's requirements and needs of growth," he says.

Articles

Foreign investment and reshoring efforts are creating near-term openings for CDMOs to support increasingly complex formulation work in the United States. Advanced dosage-form innovation is accelerating, with 3D-printed tablets positioned to expand release profiles and product differentiation, while solubility and bioavailability enhancement remains competitive but technically dynamic. Regulatory shifts at FDA are compressing development timelines, with mechanisms such as priority review vouchers intensifying speed-to-market expectations and collaboration demands. Workforce capability is being reinforced through structured internal training to improve retention and ensure continuity in client-facing execution.

Tom Sellig, Adare Pharma Solutions, shares how the CDMO is positioning for growth amid US reshoring and oral dose innovation trends.